pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·51m ago·1 min read
save

Pfizer, Lilly 'most favored nation' deals to give US share of raised foreign prices

The "most favored nation" drug pricing deals that Pfizer and Eli Lilly signed with the Trump administration suggest the companies will give the government a share of increased revenue they generate from raising prices abroad. ...

Sep 21, 2026·read at Endpoints ↗

September 21, 2026 12:14 PM EDT Pharma Pfiz­er, Lil­ly 'most fa­vored na­tion' deals to give US share of rev­enue from raised for­eign prices Drew Armstrong Executive Editor The “most fa­vored na­tion” drug pric­ing deals that Pfiz­er and Eli Lil­ly signed with the Trump ad­min­is­tra­tion sug­gest the com­pa­nies will give the gov­ern­ment a … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

source

Reporting by Endpoints.

read at Endpoints ↗
87 words · retrieved 29m ago
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
LILLY2PFIZER2ELI LILLY CO

related stories

  • Jun 8STAT+: AstraZeneca’s GLP-1 pill shows promise in obesity, diabetes trialsSTAT
  • Jun 8ADA ‘26: Lilly’s dominance, Pfizer’s ‘foundational’ drug and Roche’s ‘me-too’ optionBioPharma Dive
  • Jun 8STAT+: Pharmalittle: We’re reading about Lilly and Pfizer obesity drug data, Roche and J&J deals, and moreSTAT
  • Jun 8Major readouts from the annual diabetes conferenceSTAT
  • Jun 7STAT+: New data may cast doubt on competitiveness of Boehringer’s obesity drugSTAT